Gemcitabine-induced progressive and sustained tumour response in a patient with multi-drug resistant uterine leiomyosarcoma.

Abstract

BACKGROUND:

despite the fact that the combination of gemcitabine (GCB) and docetaxel shows an increased benefit for disease-free survival and overall survival compared to GCB alone in patients with soft-tissue sarcoma, GCB mono-chemotherapy should be considered as a preferable option with respect to the combination because of its lower toxicity profile and the possibility of it being administered continuously for a long time period.

CASE REPORT:

we report a clinical case of a woman with advanced high-grade uterine leiomyosarcoma, refractory to ifosfamide, doxorubicin and trabectedin, who experienced a sustained and progressive response to GCB alone.

CONCLUSIONS:

GCB given as mono-chemotherapy can obtain long-lasting tumour control in patients heavily pre-treated with various chemotherapeutic regimes for uterine LMS and should be considered as a possible option for this subset of patients.

• Authors: T De Pas, G Spitaleri, P D Vigna, F Toffalorio, G Curigliano, A Gambino, S Boselli, C Catania, F de Braud
• Journal: Ecancermedicalscience (Ecancermedicalscience) Vol. 2 Pg. 102 ( 2008) ISSN: 1754-6605 [Print] England
• PMID: 22275981 (Publication Type: Case Reports)